Par Drugs & Chemicals Ltd (PAR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003142, "name": "Par Drugs & Che.", "stock_name": "Par Drugs & Che.", "full_name": "Par Drugs & Chemicals Ltd", "name_url": "stocks-analysis/par-drugs-che", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "88.62", "chg": -0.26, "chgp": "-0.29%", "dir": -1, "prev_price": "88.88", "mcapval": "109.00 Cr", "mcap": "Micro Cap", "scripcode": "", "symbol": "PAR", "ind_name": "Chemicals & Petrochemicals", "ind_code": 11, "indexname": "", "isin": "INE04LG01015", "curr_date": "Mar 13", "curr_time": "", "bse_nse_vol": 6492, "exc_status": "Active", "traded_date": "Mar 13, 2026", "traded_date_str": "2026 03 13", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/par-drugs-che-1003142-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Par Drugs & Chemicals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/par-drugs-chemicals-ltd-is-rated-sell-3892037", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ParDrugsChemica_mojoScore_3892037.png", "date": "2026-03-15 10:10:32", "description": "Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Par Drugs & Chemicals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/par-drugs-chemicals-ltd-is-rated-sell-3866224", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ParDrugsChemica_mojoScore_3866224.png", "date": "2026-03-03 10:10:34", "description": "Par Drugs & Chemicals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook." }, { "title": "Par Drugs & Chemicals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/par-drugs-chemicals-ltd-is-rated-sell-3848079", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ParDrugsChemica_mojoScore_3848079.png", "date": "2026-02-20 10:10:49", "description": "Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 February 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Par Drugs & Chemicals Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/par-drugs-chemicals-ltd-valuation-shifts-signal-renewed-price-attractiveness-3846297", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ParDrugsChemica_valuationdot_3846297.png", "date": "2026-02-19 08:02:06", "description": "Par Drugs & Chemicals Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, driven primarily by its current price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a challenging recent performance relative to the Sensex, the stock’s improved valuation metrics and solid return on capital employed (ROCE) suggest a nuanced investment case for market participants." }, { "title": "Par Drugs & Chemicals Gains 5.65%: 2 Key Factors Driving the Weekly Move", "link": "https://www.marketsmojo.com/news/stocks-in-action/par-drugs-chemicals-gains-565-2-key-factors-driving-the-weekly-move-3839271", "imagepath": "", "date": "2026-02-14 11:03:04", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>09 Feb:</strong> Stock rallies 5.20% on strong volume, outperforming Sensex</p>\n <p><strong>10 Feb:</strong> Valuation shifts to fair amid mixed market performance</p>\n <p><strong>11 Feb:</strong> Q3 FY26 results reveal strong profit surge</p>\n <p><strong>12-13 Feb:</strong> Profit-taking leads to declines despite broader market weakness</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.91.72</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"st..." }, { "title": "Are Par Drugs & Chemicals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-par-drugs-chemicals-ltd-latest-results-good-or-bad-3833617", "imagepath": "", "date": "2026-02-11 19:54:18", "description": "Par Drugs & Chemicals Ltd's latest financial results for Q3 FY26 indicate a complex operational landscape. The company reported net sales of ₹29.34 crores, which represents a sequential increase of 2.37% compared to the previous quarter, marking the highest quarterly revenue on record. Year-on-year, this reflects a significant improvement of 37.23% from ₹21.38 crores in Q3 FY25. \n\nNet profit for the quarter stood at ₹4.80 crores, showing a sequential growth of 16.23% from ₹4.13 crores in Q2 FY26, and a remarkable year-on-year increase of 727.59%. The profit after tax (PAT) margin also expanded to 16.36%, up from 14.41% in the previous quarter, indicating improved profitability.\n\nHowever, the operating margin, excluding other income, was reported at 20.65%, which is slightly lower than the 21.18% recorded in Q2 FY26, although it is significantly higher than the 6.64% from the same quarter last year. This yea..." }, { "title": "Par Drugs & Chemicals Q3 FY26: Strong Profit Surge Masks Troubling Long-Term Trajectory", "link": "https://www.marketsmojo.com/news/result-analysis/par-drugs-chemicals-q3-fy26-strong-profit-surge-masks-troubling-long-term-trajectory-3832995", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ParDrugsChemica_quaterlyResult_3832995.png", "date": "2026-02-11 09:48:39", "description": "Par Drugs and Chemicals Ltd., a micro-cap chemical manufacturer with a market capitalisation of ₹124.83 crores, delivered a robust quarterly performance in Q3 FY26, posting net profit of ₹4.80 crores—a sharp 16.23% quarter-on-quarter increase and a remarkable 727.59% year-on-year surge. However, this impressive quarterly snapshot conceals deeper structural concerns that have plagued the company's long-term trajectory, with the stock down 41.57% over the past year despite the recent operational uptick." }, { "title": "Are Par Drugs & Chemicals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-par-drugs-chemicals-ltd-latest-results-good-or-bad-3831622", "imagepath": "", "date": "2026-02-10 19:39:36", "description": "Par Drugs & Chemicals Ltd's latest financial results for the quarter ending September 2025 reveal a complex operational landscape. The company reported a net profit of ₹4.13 crores, reflecting a quarter-on-quarter increase of 24.02%, while year-on-year performance showed a decline of 51.98%. Revenue for the same period reached ₹28.66 crores, marking a 10.02% increase from the previous quarter, but a significant year-on-year decrease of 17.31% compared to ₹34.66 crores in the same quarter last year.\n\nThe operating margin improved to 21.18%, up from 13.67% in the prior quarter, indicating some recovery in profitability. However, this figure remains below the 32.92% margin achieved in the corresponding quarter of the previous year, highlighting ongoing challenges in maintaining operational efficiency. The profit after tax (PAT) margin also saw a quarter-on-quarter improvement to 14.41%, but again, this is down..." }, { "title": "Par Drugs & Chemicals Ltd Valuation Shifts to Fair Amid Mixed Market Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/par-drugs-chemicals-ltd-valuation-shifts-to-fair-amid-mixed-market-performance-3829734", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ParDrugsChemica_valuationdot_3829734.png", "date": "2026-02-10 08:03:20", "description": "Par Drugs & Chemicals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions and sector dynamics. Despite a recent 5.2% intraday price gain, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more cautious outlook compared to its historical benchmarks and peer group averages." } ], "total": 116, "sid": "1003142", "stock_news_url": "https://www.marketsmojo.com/news/par-drugs-chemicals-1003142" }, "announcements": [ { "details": "Par Drugs And Chemicals Limited has informed the Exchange regarding Board meeting held on November 11, 2019.", "source": "NSE", "caption": "Par Drugs And Chemicals Limited - Outcome of Board Meeting", "datetime": "13-Nov-2019" }, { "details": "Par Drugs And Chemicals Limited has informed the Exchange that the Company has fixed Record Date as November 25, 2019 for the purpose of INTERIM DIVIDEND", "source": "NSE", "caption": "Par Drugs And Chemicals Limited - Record Date", "datetime": "04-Nov-2019" }, { "details": "Par Drugs And Chemicals Limited has informed the Exchange regarding 'WHO-GMP Certification'.", "source": "NSE", "caption": "Par Drugs And Chemicals Limited - Updates", "datetime": "30-Oct-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Par Drugs & Chemicals Ltd has declared <strong>12%</strong> dividend, ex-date: 22 Nov 21", "dt": "2021-11-22", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Par Drugs & Chemicals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 27 Apr 21", "dt": "2021-04-27", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

09 Feb: Stock rallies 5.20% on strong volume, outperforming Sensex

10 Feb: Valuation shifts to fair amid mixed market performance

11 Feb: Q3 FY26 results reveal strong profit surge

12-13 Feb: Profit-taking leads to declines despite broader market weakness

Week Open

Rs.91.72

Week Close

Read full news article

Are Par Drugs & Chemicals Ltd latest results good or bad?

2026-02-11 19:54:18

Par Drugs & Chemicals Ltd's latest financial results for Q3 FY26 indicate a complex operational landscape. The company reported net sales of ₹29.34 crores, which represents a sequential increase of 2.37% compared to the previous quarter, marking the highest quarterly revenue on record. Year-on-year, this reflects a significant improvement of 37.23% from ₹21.38 crores in Q3 FY25. Net profit for the quarter stood at ₹4.80 crores, showing a sequential growth of 16.23% from ₹4.13 crores in Q2 FY26, and a remarkable year-on-year increase of 727.59%. The profit after tax (PAT) margin also expanded to 16.36%, up from 14.41% in the previous quarter, indicating improved profitability. However, the operating margin, excluding other income, was reported at 20.65%, which is slightly lower than the 21.18% recorded in Q2 FY26, although it is significantly higher than the 6.64% from the same quarter last year. This yea...

Read full news article

Par Drugs & Chemicals Q3 FY26: Strong Profit Surge Masks Troubling Long-Term Trajectory

2026-02-11 09:48:39

Par Drugs and Chemicals Ltd., a micro-cap chemical manufacturer with a market capitalisation of ₹124.83 crores, delivered a robust quarterly performance in Q3 FY26, posting net profit of ₹4.80 crores—a sharp 16.23% quarter-on-quarter increase and a remarkable 727.59% year-on-year surge. However, this impressive quarterly snapshot conceals deeper structural concerns that have plagued the company's long-term trajectory, with the stock down 41.57% over the past year despite the recent operational uptick.

Read full news article

Are Par Drugs & Chemicals Ltd latest results good or bad?

2026-02-10 19:39:36

Par Drugs & Chemicals Ltd's latest financial results for the quarter ending September 2025 reveal a complex operational landscape. The company reported a net profit of ₹4.13 crores, reflecting a quarter-on-quarter increase of 24.02%, while year-on-year performance showed a decline of 51.98%. Revenue for the same period reached ₹28.66 crores, marking a 10.02% increase from the previous quarter, but a significant year-on-year decrease of 17.31% compared to ₹34.66 crores in the same quarter last year. The operating margin improved to 21.18%, up from 13.67% in the prior quarter, indicating some recovery in profitability. However, this figure remains below the 32.92% margin achieved in the corresponding quarter of the previous year, highlighting ongoing challenges in maintaining operational efficiency. The profit after tax (PAT) margin also saw a quarter-on-quarter improvement to 14.41%, but again, this is down...

Read full news article

Par Drugs & Chemicals Ltd Valuation Shifts to Fair Amid Mixed Market Performance

2026-02-10 08:03:20

Par Drugs & Chemicals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions and sector dynamics. Despite a recent 5.2% intraday price gain, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more cautious outlook compared to its historical benchmarks and peer group averages.

Read full news article